Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
‘Human Error' Caused Contamination Of Moderna Vaccines In Japan, Distributor Takeda Says
06:10am, Friday, 01'st Oct 2021
An investigation carried out by Moderna and the Spanish manufacturer Rovi found that the issue was caused by incorrect assembly of the vaccine vials
Takeda In-Licenses Hunter Syndrome Candidate
07:18am, Thursday, 30'th Sep 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to commercialize JR-141 (pabinafusp alfa) for Hunt
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
04:00am, Thursday, 30'th Sep 2021
OSAKA, Japan & ASHIYA, Hyogo, Japan--(BUSINESS WIRE)--Takeda and JCR announced an exclusive collaboration and license agreement to commercialize JR-141 for the treatment of Hunter syndrome.
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
01:16pm, Friday, 24'th Sep 2021
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in favor of AbbVie. The new ruling found that
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
09:57am, Wednesday, 22'nd Sep 2021
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the addition of four partnerships to its Global Corporate Social Responsibility
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
11:00am, Tuesday, 21'st Sep 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome (A
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
06:08am, Thursday, 16'th Sep 2021
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for adult patients with locally advanced
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved
Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
08:51pm, Monday, 13'th Sep 2021
Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory appr
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
11:27am, Friday, 03'rd Sep 2021
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
10:13am, Thursday, 02'nd Sep 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did not achieve the pre-defined statist
3 Blue-Chips With 52%-164% Upside According To Wall Street
11:19pm, Wednesday, 01'st Sep 2021
3 Blue-Chips With 52%-164% Upside According To Wall Street
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
04:31pm, Wednesday, 01'st Sep 2021
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not ac
The Partnership Effect: Arrowhead Forges Its Future
09:37pm, Thursday, 26'th Aug 2021
The Partnership Effect: Arrowhead Forges Its Future
